Bayrak S, Mitchison N A
Deutsches Rheumaforschungszentrum, Berlin, Germany.
Clin Exp Immunol. 1998 Jul;113(1):92-5. doi: 10.1046/j.1365-2249.1998.00638.x.
Oral and more recently nasal tolerance have attracted attention as potential treatments of autoimmune disease. Arthritis induced by bovine type II collagen (CII) is a widely used animal model of rheumatoid arthritis, which is here used to investigate the efficacy of nasal treatment by a short peptide. The peptide spans residues 707-721 (designated p707), an epitope of mouse CII that is most strongly recognized after immunization of mice with this self-protein. The treatment was partially effective, but almost only when the peptide was administered in large doses over a prolonged period. Mice immunized with bovine CII respond mainly to other peptides, located in the CB11 fragment around amino acid residues 256-270. The tolerance effect therefore results from intramolecular suppression, between epitopes located in different parts of this large protein.
口服耐受性以及最近的鼻内耐受性作为自身免疫性疾病的潜在治疗方法已引起关注。牛II型胶原蛋白（CII）诱导的关节炎是类风湿性关节炎广泛使用的动物模型，在此用于研究短肽鼻内治疗的疗效。该肽跨越第707 - 721位氨基酸残基（命名为p707），是小鼠CII的一个表位，在用这种自身蛋白免疫小鼠后，该表位得到最强烈的识别。该治疗部分有效，但几乎仅在长时间大剂量给予该肽时才有效。用牛CII免疫的小鼠主要对位于氨基酸残基256 - 270周围的CB11片段中的其他肽产生反应。因此，耐受效应是由位于这种大蛋白不同部位的表位之间的分子内抑制引起的。
